|
1
|
Alberg AJ and Samet JM: Epidemiology of
lung cancer. Chest. 123:21–49. 2003. View Article : Google Scholar
|
|
2
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Alberg AJ, Ford JG and Samet JM:
Epidemiology of lung cancer: ACCP evidence-based clinical practice
guidelines. Chest. 132:29S–55S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paesmans M, Sculier JP, Libert P, et al:
Prognostic factors for survival in advanced non-small-cell lung
cancer: univariate and multivariate analyses including recursive
partitioning and amalgamation algorithms in 1,052 patients. The
European Lung Cancer Working Party. J Clin Oncol. 13:1221–1230.
1995.
|
|
5
|
Rothberg KG, Heuser JE, Donzell WC, et al:
Caveolin, a protein component of caveolae membrane coats. Cell.
68:673–682. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sloan EK, Stanley KL and Anderson RL:
Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene.
23:7893–7897. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Williams TM, Medina F, Badano I, et al:
Caveolin-1 gene disruption promotes mammary tumorigenesis and
dramatically enhances lung metastasis in vivo: role of Cav-1 in
cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion.
J Biol Chem. 279:51630–51646. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Razani B, Altschuler Y, Zhu L, et al:
Caveolin-1 expression is down-regulated in cells transformed by the
human papilloma virus in a p53-dependent manner. Replacement of
caveolin-1 expression suppresses HPV-mediated cell transformation.
Biochemistry. 39:13916–13924. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Racine C, Belanger M, Hirabayashi H, et
al: Reduction of caveolin 1 gene expression in lung carcinoma cell
lines. Biochem Biophys Res Commun. 255:580–586. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sunaga N, Miyajima K, Suzuki M, et al:
Different roles for caveolin-1 in the development of non-small cell
lung cancer versus small cell lung cancer. Cancer Res.
64:4277–4285. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiechen K, Diatchenko L, Agoulnik A, et
al: Caveolin-1 is down-regulated in human ovarian carcinoma and
acts as a candidate tumor suppressor gene. Am J Pathol.
159:1635–1643. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Galbiati F, Volonte D, Engelman JA, et al:
Targeted downregulation of caveolin-1 is sufficient to drive cell
transformation and hyperactivate the p42/44 MAP kinase cascade.
EMBO J. 17:6633–6648. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koleske AJ, Baltimore D and Lisanti MP:
Reduction of caveolin and caveolae in oncogenically transformed
cells. Proc Natl Acad Sci USA. 92:1381–1385. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fong A, Garcia E, Gwynn L, et al:
Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of
the urinary bladder correlates with tumor grade and squamous
differentiation. Am J Clin Pathol. 120:93–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu YC, Lam KY, Law S, et al: Profiling of
differentially expressed cancer-related genes in esophageal
squamous cell carcinoma (ESCC) using human cancer cDNA arrays:
overexpression of oncogene MET correlates with tumor
differentiation in ESCC. Clin Cancer Res. 7:3519–3525. 2001.
|
|
16
|
Li L, Yang G, Ebara S, et al: Caveolin-1
mediates testosterone stimulate survival/clonal growth and promotes
metastatic activities in prostate cancer cells. Cancer Res.
61:4386–4392. 2001.PubMed/NCBI
|
|
17
|
Kato K, Hida Y, Miyamoto M, et al:
Overexpression of caveolin-1 in esophageal squamous cell carcinoma
correlates with lymph node metastasis and pathologic stage. Cancer.
94:929–933. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang G, Truong LD, Wheeler TM, et al:
Caveolin-1 expression in clinically confined human prostate cancer:
a novel prognostic marker. Cancer Res. 59:5719–5723.
1999.PubMed/NCBI
|
|
19
|
Ho CC, Huang PH, Huang HY, et al:
Up-regulated caveolin-1 accentuates the metastasis capability of
lung adenocarcinoma by inducing filopodia formation. Am J Pathol.
161:1647–1656. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yoo SH, Park YS, Kim HR, et al: Expression
of caveolin-1 is associated with poor prognosis of patients with
squamous cell carcinoma of the lung. Lung Cancer. 42:195–202. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moon KC, Lee GK, Yoo SH, et al: Expression
of caveolin-1 in pleomorphic carcinoma of the lung is correlated
with a poor prognosis. Anticancer Res. 25:4631–4637.
2005.PubMed/NCBI
|
|
22
|
Kato T, Miyamoto M, Kato K, et al:
Difference of caveolin-1 expression pattern in human lung
neoplastic tissue. Atypical adenomatous hyperplasia, adenocarcinoma
and squamous cell carcinoma. Cancer Lett. 214:121–128. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wikman H, Seppänen JK, Sarhadi VK, et al:
Caveolins as tumour markers in lung cancer detected by combined use
of cDNA and tissue microarrays. J Pathol. 203:584–593. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ho CC, Kuo SH, Huang PH, et al: Caveolin-1
expression is significantly associated with drug resistance and
poor prognosis in advanced non-small cell lung cancer patients
treated with gemcitabine-based chemotherapy. Lung Cancer.
59:105–110. 2008. View Article : Google Scholar
|
|
25
|
Groome PA, Bolejack V, Crowley JJ, et al;
IASLC International Staging Committee; Cancer Research and
Biostatistics; Observers to the Committee; Participating
Institutions. The IASLC Lung Cancer Staging Project: validation of
the proposals for revision of the T, N and M descriptors and
consequent stage groupings in the forthcoming (seventh) edition of
the TNM classification of malignant tumours. J Thorac Oncol.
2:694–705. 2007. View Article : Google Scholar
|
|
26
|
Li S, Couet J and Lisanti MP: Src tyrosine
kinases, Galpha subunits, and H-Ras share a common
membrane-anchored scaffolding protein, caveolin: caveolin binding
negatively regulates the auto-activation of Src tyrosine kinases. J
Biol Chem. 271:29182–29190. 1996. View Article : Google Scholar
|
|
27
|
Oka N, Yamamoto M, Schwencke C, et al:
Caveolin interaction with protein kinase C: isoenzyme-dependent
regulation of kinase activity by the caveolin scaffolding domain
peptide. J Biol Chem. 272:33416–33421. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Couet J, Sargiacomo M and Lisanti MP:
Interaction of a receptor tyrosine kinase, EGF-R, with caveolins:
caveolin binding negatively regulates tyrosine and serine/threonine
kinase activities. J Biol Chem. 272:30429–30438. 1997. View Article : Google Scholar
|
|
29
|
Razani B, Zhang XL, Bitzer M, et al:
Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD
signaling through an interaction with the TGF-beta type I receptor.
J Biol Chem. 276:6727–6738. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Galbiati F, Volonte D, Brown AM, et al:
Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by
recruiting beta-catenin to caveolae membrane domains. J Biol Chem.
275:23368–23377. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Campbell L, Hollins AJ, Al-Eid A, et al:
Caveolin-1 expression and caveolae biogenesis during cell
transdifferentiation in lung alveolar epithelial primary cultures.
Biochem Biophys Res Commun. 262:744–751. 1999. View Article : Google Scholar : PubMed/NCBI
|
